Antonio De Vincentis1, Paolo Gallo2,3, Panaiotis Finamore1, Claudio Pedone1, Luisa Costanzo1, Luca Pasina4, Laura Cortesi4, Alessandro Nobili4, Pier Mannuccio Mannucci5, Raffaele Antonelli Incalzi1. 1. Unit of Geriatrics, Campus Bio-Medico University of Rome, Via Alvaro del Portillo, 200, 00128, Rome, Italy. 2. Unit of Geriatrics, Campus Bio-Medico University of Rome, Via Alvaro del Portillo, 200, 00128, Rome, Italy. paolo.gallo@unicampus.it. 3. Unit of Internal Medicine and Hepatology, University Campus Bio-Medico, Rome, Italy. paolo.gallo@unicampus.it. 4. Dipartimento di Neuroscienze, IRCCS-Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy. 5. IRCCS Ca' Granda Maggiore Hospital Foundation and University of Milan, Milan, Italy.
Abstract
BACKGROUND: Polypharmacy is very common in elderly patients and is associated with detrimental outcomes. OBJECTIVE: Our objective was to evaluate the associations between a large panel of therapy quality indicators, including explicit lists of potentially inappropriate medications (PIMs; Beers criteria and Screening Tool of Older Persons' potentially inappropriate Prescriptions [STOPP] criteria), the Anticholinergic Cognitive Burden (ACB) score, and the number of drug-drug interactions (DDIs), with respect to mortality, rehospitalization, and physical function decline within 3 months from hospital discharge in a cohort of hospitalized elderly patients. METHODS: We studied 2631 individuals aged ≥ 65 years (median age 79.6; males 48.6%) enrolled in the REPOSI registry. The relationships with mortality and rehospitalization were evaluated using Cox regressions, and relationships with functional status change (as percentage variation of Barthel Index [BI]) were evaluated using mixed linear models. RESULTS: None of the studied indicators was associated with mortality and rehospitalization. Conversely, only ACB was associated with physical function decline, even after correction for confounders (adjusted mean BI variation of - 7.55%; 95% confidence interval [CI] - 12.37 to - 2.47). The number of medications at discharge, particularly polypharmacy (more than five drugs daily), were the only therapy-related factors associated with mortality (adjusted hazard ratio [aHR] 1.05 [95% CI 1.01-1.10] and 1.70 [95% CI 1.12-2.58], respectively) and rehospitalization (aHR 1.05 [95% CI 1.01-1.08] and 1.31 [95% CI 1.01-1.71], respectively). CONCLUSION: Polypharmacy, a very simple measure, outperformed sophisticated PIM and DDI indicators of quality of therapy as a correlate of primary clinical outcomes, whereas ACB was associated with physical function decline. Thus, innovative approaches to the definition and research of PIMs and DDIs are eagerly awaited from the perspective of averaging the quantitative burden and qualitative interaction of drugs.
BACKGROUND: Polypharmacy is very common in elderly patients and is associated with detrimental outcomes. OBJECTIVE: Our objective was to evaluate the associations between a large panel of therapy quality indicators, including explicit lists of potentially inappropriate medications (PIMs; Beers criteria and Screening Tool of Older Persons' potentially inappropriate Prescriptions [STOPP] criteria), the Anticholinergic Cognitive Burden (ACB) score, and the number of drug-drug interactions (DDIs), with respect to mortality, rehospitalization, and physical function decline within 3 months from hospital discharge in a cohort of hospitalized elderly patients. METHODS: We studied 2631 individuals aged ≥ 65 years (median age 79.6; males 48.6%) enrolled in the REPOSI registry. The relationships with mortality and rehospitalization were evaluated using Cox regressions, and relationships with functional status change (as percentage variation of Barthel Index [BI]) were evaluated using mixed linear models. RESULTS: None of the studied indicators was associated with mortality and rehospitalization. Conversely, only ACB was associated with physical function decline, even after correction for confounders (adjusted mean BI variation of - 7.55%; 95% confidence interval [CI] - 12.37 to - 2.47). The number of medications at discharge, particularly polypharmacy (more than five drugs daily), were the only therapy-related factors associated with mortality (adjusted hazard ratio [aHR] 1.05 [95% CI 1.01-1.10] and 1.70 [95% CI 1.12-2.58], respectively) and rehospitalization (aHR 1.05 [95% CI 1.01-1.08] and 1.31 [95% CI 1.01-1.71], respectively). CONCLUSION: Polypharmacy, a very simple measure, outperformed sophisticated PIM and DDI indicators of quality of therapy as a correlate of primary clinical outcomes, whereas ACB was associated with physical function decline. Thus, innovative approaches to the definition and research of PIMs and DDIs are eagerly awaited from the perspective of averaging the quantitative burden and qualitative interaction of drugs.
Authors: Michael A Steinman; C Seth Landefeld; Gary E Rosenthal; Daniel Berthenthal; Saunak Sen; Peter J Kaboli Journal: J Am Geriatr Soc Date: 2006-10 Impact factor: 5.562
Authors: A Nobili; L Pasina; M Tettamanti; U Lucca; E Riva; I Marzona; L Monesi; R Cucchiani; A Bortolotti; I Fortino; L Merlino; G Walter Locatelli; G Giuliani Journal: J Clin Pharm Ther Date: 2009-08 Impact factor: 2.512
Authors: Antonio De Vincentis; Astrid Ursula Behr; Giuseppe Bellelli; Marco Bravi; Anna Castaldo; Lucia Galluzzo; Giovanni Iolascon; Stefania Maggi; Emilio Martini; Alberto Momoli; Graziano Onder; Marco Paoletta; Luca Pietrogrande; Mauro Roselli; Mauro Ruggeri; Carmelinda Ruggiero; Fabio Santacaterina; Luigi Tritapepe; Amedeo Zurlo; Raffaele Antonelli Incalzi Journal: Aging Clin Exp Res Date: 2021-07-21 Impact factor: 3.636
Authors: Gloria Liquori; Aurora De Leo; Emanuele Di Simone; Sara Dionisi; Noemi Giannetta; Elvira Ganci; Sherly Pia Trainito; Giovanni Battista Orsi; Marco Di Muzio; Christian Napoli Journal: Int J Environ Res Public Health Date: 2022-04-25 Impact factor: 4.614
Authors: Labib Al-Musawe; Carla Torre; Jose Pedro Guerreiro; Antonio Teixeira Rodrigues; Joao Filipe Raposo; Helder Mota-Filipe; Ana Paula Martins Journal: Pharmacol Res Perspect Date: 2020-08
Authors: Natacha Christina de Araújo; Erika Aparecida Silveira; Brenda Godoi Mota; João Paulo Neves Mota; Ana Elisa Bauer de Camargo Silva; Rafael Alves Guimarães; Valéria Pagotto Journal: PLoS One Date: 2020-10-28 Impact factor: 3.240